Abiopharma

New Form 144 - Arcutis Biotherapeutics, Inc. Filed: 2025-09-09 AccNo: 0002007317-25-001055 Size: 5 KB

New Form 144 - CORE MOLDING TECHNOLOGIES INC Filed: 2025-09-09 AccNo: 0001949846-25-000456 Size: 8 KB

New Form 6-K - GENMAB A/S Filed: 2025-09-09 AccNo: 0001434265-25-000074 Size: 225 KB

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Capital Increase in Genmab as a Result of Employee Warrant Exercise

França concede acesso compassivo (AAC) reembolsável ao BOT/BAL da Agenus no câncer colorretal metastático MSS refratário

Francia otorga acceso compasivo (AAC) reembolsado para el tratamiento BOT/BAL de Agenus en el cáncer colorrectal metastásico refractario con MSS

La Francia concede laccesso compassionevole (AAC) rimborsato per BOT/BAL di Agenus nel tumore colorettale metastatico MSS

フランス、難治性MSS転移性大腸がんにおけるアジーナスのBOT/BALに償還付きコンパッショネートアクセス（AAC）を承認

法國核准Agenus的BOT/BAL用於難治性MSS轉移性大腸癌的同情用藥報銷(AAC)

法国批准Agenus的BOT/BAL用于难治性MSS转移性结直肠癌的同情用药报销(AAC)

Frankrijk verleent vergoede compassionate access (AAC) voor BOT/BAL van Agenus bij refractaire MSS-gemetastaseerde colorectale kanker

La France accorde une autorisation daccès compassionnel remboursable au BOT/BAL d’Agenus dans le cancer colorectal métastatique MSS réfractaire

FDA approve BIMATOPROST

Everything Announced at Apple’s “Awe Dropping” Event — iPhone 17, iOS 26, Apple Watch Ultra 3